Meeder Asset Management’s Travere Therapeutics TVTX Stock Holding History

Meeder Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-728	Closed	-$18K	–	2663
2021 Q1	$18K	Buy	+728	New	+$20.1K	﹤0.01%	1445
2020 Q4	–	Sell	-1,438	Closed	-$26K	–	2222
2020 Q3	$26K	Buy	+1,438	New	+$27.9K	﹤0.01%	1097
2020 Q1	–	Sell	-1,645	Closed	-$23K	–	2534
2019 Q4	$23K	Sell	1,645 -2,366	-59%	-$30.2K	﹤0.01%	1308
2019 Q3	$47K	Buy	4,011 +3,470	+641%	+$57.3K	﹤0.01%	1039
2019 Q2	$11K	Buy	+541	New	+$10.7K	﹤0.01%	1434
2018 Q4	–	Sell	-4,663	Closed	-$135K	–	1809
2018 Q3	$135K	Buy	4,663 +3,541	+316%	+$101K	0.01%	581
2018 Q2	$30.6K	Buy	1,122 +268	+31%	+$7.14K	﹤0.01%	874
2018 Q1	$19K	Buy	854 +433	+103%	+$10.3K	﹤0.01%	905
2017 Q4	$9K	Buy	421 +296	+237%	+$6.76K	﹤0.01%	1164
2017 Q3	$3K	Buy	+125	New	+$2.75K	﹤0.01%	1387
2017 Q2	–	Sell	-766	Closed	-$14K	–	1879
2017 Q1	$14K	Buy	+766	New	+$15K	﹤0.01%	789

Other funds holding TVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Meeder Asset Management's TVTX Position: Q2 2021 in Review

Meeder Asset Management sold out of Travere Therapeutics (TVTX) in Q2 2021, closing a stake of 728 shares — an estimated $18K sold.

Meeder Asset Management first reported a position in TVTX in Q1 2017 and held it in 11 quarters. The position peaked at $135K in Q3 2018. 136 funds tracked by Wall St. Rank hold TVTX as of Q2 2021.

Meeder Asset Management reported no remaining Travere Therapeutics position as of Q2 2021 after selling out during the quarter.
Meeder Asset Management sold 728 Travere Therapeutics shares in Q2 2021, an estimated $18K.
Meeder Asset Management first reported a position in Travere Therapeutics in Q1 2017 and held it in 11 quarters.
Meeder Asset Management's Travere Therapeutics position peaked at $135K in Q3 2018.
136 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2021.

Based on Meeder Asset Management's 13F filing for Q2 2021, filed 9 Aug 2021.